A new rapamycin producing culture was isolated and designated as Actinoplanes sp. N902-109.
Rapamycin is a 31-membered macrocyclic lactone known to be produced by Streptomyces hygroscopicus ATCC 292531>2). Although rapamycin was originally isolated as an antifungal agent, its immunosuppressive effect has recently attracted more attention. In the last few years this interest has been heightened, because its mechanismof action appears to be different from that of FK506, a structurally related immunosuppressive agent produced by Streptomyces tsukubaensis No. 99933).
Thus, while both rapamycin and FK506 bind to a family of proteins called FKBP, the subsequent steps of T cell activation appear to be different40. Whereas the target of the FK506-FKBPcomplex has been established to be calcineurin, a protein phosphatase, a purported effector molecule of the rapamycin-FKBP complex has been reported only very recently5~7). The biosynthetic pathway of rapamycin has been postulated and substantiated by labelling studies using acetate, propionate and methionine8). According to this scheme, the majority of the rapamycin macrolide ring (except carbons 12 and 13) is formed from 6 acetate and 7 propionate units. The C7 unit containing the cyclohexyl ring is derived from the shikimic acid pathway, and the pipecolic acid moiety is expected to be derived from this amino acid or lysine. This biosynthetic pathway suggests that the oxygen functionalities at C-9 and C-27 are added in the succeeding steps, which in turn suggests that addition of a P-450 inhibitor can generate analogs of different oxidation states. The proposed incorporation of pipecolic acid suggests that other amino acids might 657 be likewise incorporated. In addition, biotransformation techniques often provide specific reactions under mild conditions for conversions of complex molecules containing sensitive functionalities. FK506 has been successfully biotransformed to generate novel analogs9).
As part of a program aimed at discovering novel immunosuppressive agents, we have identified a new rapamycin producing culture, designated Actinoplanes sp. N902-109. In order to generate novel analogs with potentially reduced renal and CNStoxicity associated with existing immunosuppressive agents, we have investigated microbial manipulations such as addition of a cytochrome P-450 inhibitor, precursor feeding and biotransformation approaches. In this paper, we describe taxonomy of the producing organism, fermentation, isolation, structure elucidation and biological activities of the new rapamycin analogs (Fig. 1 ).
Results

Taxonomy
A culture, designated N902-109, was isolated from a soil sample collected in Shizuoka Prefecture, Japan. Aerial mycelium was absent. The substrate mycelium mostly ranged from orange yellow, orange, bright orange to dark orange; it was dark brown on tyrosine agar, and pale pink to pale lavender on Czapek-sucrose agar. The soluble pigment, if present, was pale yellow to yellow brown (Table 1) . Whengrown on M3agar10) for three weeks, spores were produced in compact chains and
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.
Except for the absence of a sporangial wall, the culture resembles A. kanagawaensis12), A. missouriensis Couch, A. auranticolor (Couch) Palleroni, and A. teichomyceticus Parenti, Beretta, Berti & Arioli. However, it differs from A. kanagawaensis and A. auranticolor in the failure to produce hydrogen sulfide, the ability to coagulate milk, and the failure to utilize rhamnose. It is different from A. missouriensis in its failure to reduce nitrate and its failure to utilize rhamnose. Although it shares the same pattern of carbohydrate utilization with A. teichomyceticus, it differs by the smaller sporangia (spore clusters) and spores, the failure to produce melanin and hydrogen sulfide, the failure to reduce nitrate, and the ability to coagulate milk ( Table  2 ). In a lack of sporangial wall, the culture resembles members of the recently described genus Couchioplanes, from which it differs in the presence of raeso-diaminopimelic acid. On the basis of these results, the culture N902-109 is tentatively assigned to the genus Actinoplanes and considered as Actinoplanes sp. It has been deposited at the National Institute of Bioscience and Microbial Manipulations Cytochrome P-450 Inhibitor Addition The newrapamycin producer, Actinoplanes sp. N902-109 grown in a production medium described in the experimental section produced rapamycin at lOO mg/liter level as shown in Fig. 2A . Five mMof metyrapone (cytochrome P-450 inhibitor) was added to the culture to suppress rapamycin production. As a result, 4 rapamycin analogs CJ- 1 2,452 (28- Fig. 2C . Furthermore, in order to replace the L-pipecolic acid moiety by other amino acids, a variety of substrates were fed to the rapamycin producer. When L-proline was fed to the fermentation broth, two rapamycin analogs, 797 (prolylrapamycin, 25 mg/liter) and  25 mg/ liter) were detected by HPLC (Fig. 2D ). Biotransformation Biotransformation of rapamycin was examined by using the 34 actinomycetes (15 macrolide and 19 polyether producers). One of them, the culture Streptomyces toyocaensis subsp. humicola ATCC39471 was found to transform rapamycin to at the conversion ratio of 50% (Fig. 2E ).
Biological Activity
The mixed lymphocyte reaction (MLR) inhibitory activity of the new rapamycin analogs is shown in Table 3 inhibitor, precursor feeding and biotransformation, and generated 1 1 new rapamycin analogs ( Fig. 1 ). In the past, cytochrome P-450 inhibitors have been utilized to study the biosynthesis of natural products. For example, the cytochrome P-450 inhibitors S-33070 and ancymidol have been used to generate new analogs ofchaetoglobosin and nigericin, respectively13). We used commercially available metyrapone as a cytochrome P-450 inhibitor. Addition of this agent to the fermentation medium generated 4 new analogs, which are 9-deoxo-and/or 27-demethoxy analogs 573, 575 and CJ-12,578), as expected from the postulated biosynthetic pathway and a 28-dehydroxy analog (CJ-12,452). Detection of the 28-dehydroxy analog indicates that the initial oxygen atom from the acetate carbonyl group has been further removedin the presence of metyrapone.
Addition of L-pipecolic acid increased the titer of minor components 225, 263, 265) , resulting in the total titer of 450mg/liter. This appears to substantiate the proposal for the origins of this pipecolinyl group. Addition of L-proline caused the production of a prolyl analog (CJ-12,797) and a 27-0-demethylprolyl analog 798) . In this case, rapamycin was also coproduced by the normal biosynthetic pathway (Fig. 2D) . The potency of these analogs in the MLRassay is listed in Table 3 . The potency of the analogs ranges from Comparison of rapamyein and its 27-0-demethyl analog 264) shows that loss of a methyl group at C-27 does not affect activity. This is also apparent in the prolylrapamycin pair CJ-12,797 and CJ-12,798. Loss of a methyl group at C-16 or a simultaneous loss ofmethyl groups at both C-16 and C-27, again has little effect on potency 263, 225) . Loss of the methoxy functionality at C-27, however, causes fairly drastic reduction in potency, as can be seen in the rapamycin and 27-demethoxyrapamycin pair and in the 39-O-demethylrapamycin (CJ-12,434) and 27-demethoxy-39-O-demethylrapamycin (CJ-12,264) pair. Neither the C-16 nor the C-27 position is involved in binding to FKBP14), and both positions are postulated to be involved in interacting with the effector molecule5~7), although little is known about this interaction at present. The C-28 hydroxy group is critical for MLRactivity, since C-28 dehydroxyrapamycin (CJ-12,452) has approximately 380-fold less potency compared to rapamycin. The C-28 hydroxy group has been described to form a hydrogen bond to the amide carbonyl group of Glu-54 of FKBP14). 9-Deoxorapamycin (CJ-12,573) is approximately 40 times less potent than rapamycin. The interesting fact, however, is that the 9-deoxo analog retains activity.
This suggests that other structures without the tricarbonyl moiety may exhibit activity. It is known that the C-9 carbonyl group does not form hydrogen bonds to FKBP14).
Substitution ofa prolyl group for the pipecolinyl group reduces potency 20-fold. According to published X-ray and NMRstudies14), this region of rapamycin is most deeply imbedded in the rapamycin-FKBP complex, and it is in contact with lipophilic residues of FKBP. The observed loss in potency can be ascribed to reduced hydrophobic interaction between prolylrapamycin and the FKBP pocket. demonstrated inhibitory activity of mitogen-stimulated human mononuclear cells proliferation and in vivo activity. Chemical modifications at C-40 position have been claimed to retain the immunosuppressive activity15'16).
This suggests that cyclohexyl ring in rapamycin can be a target for generation of further analogs with improved bioavailability.
Since 263, 265, 225 retained MLRactivity comparable to rapamycin, these compounds might be of interest for further biological evaluation.
Although numerous semisynthetic derivatives of rapa- 0.0001% CoCl2-6H2O and 0.3% CaCO3 (adjusted to pH 7.0). The fermentation was carried out at 28°C for a day with an aeration rate of 3 liters/minute and an agitation rate at 1,700 rpm and then 5 mMofmetyrapone (2-methyl-l ,2-di-3-pyridyl-l-propanone) were added to the cultured broth. The broth was subsequently incubated for 3 days under the same conditions.
Precursor Feeding
The culture N902-109 was maintained on ATCC172 medium. A vegetative cell suspension of the slant culture ofN902-109 was inoculated into a 500-ml flask (first seed culture) containing 100 ml of the seed medium(medium A). The flask was incubated on a rotary shaker (220 rpm) at 28°C for 4 days. The first seed culture (15ml) was transferred to two 500-ml flasks (second seed culture), each containing 150ml of the medium A and incubated on a rotary shaker at 28°C for 4 days. The second seed culture (300ml) was transferred to two 6-liter jar fermentors with a small propeller-type impeller (7cm diameter), each containing 3 liters of the production medium (medium B). The fermentation was carried out at 28°C for a day with an aeration rate of 3 liters/minute and an agitation rate at 1,700rpm and then precursor (L-pipecolic acid or L-proline) was added to the cultured broth at the final concentration of 1 mg/ml. The broths were subsequently incubated for 3 days under the same conditions.
Biotransformation by Streptomyces toyocaensis ATCC 39471
The culture Streptomyces toyocaensis subsp. humicola ATCC39471 was maintained on ATCC172 medium. A loopful ofmycelial suspension from the slant culture was inoculated into a flask (500ml) containing 100ml of the seed medium (medium A). The flask was incubated on a rotary shaker (220rpm) at 28°C for 4 days. The first seed culture (15 ml) was transferred to two 500-ml flasks (second seed culture), each containing 150ml of the mediumA and incubated on a rotary shaker at 28°C for 4 days. The second seed culture (300 ml) was transferred to two 6-liter jar fermentors with a small propeller-type impeller (7cm diameter), each containing 3 liters of fermentation medium, consisting of 1.0% glucose, 2.0% corn starch, 0.5% NZAmine type A, 0.5% wheat embryo, 0.5% yeast extract, 0.0001% CoQ2-6H2O and 0.4% CaCO3(adjusted to pH 7.2~7.4). Fermentation was carried out at 28°C for 24 hours with an aeration rate of 3 liters/minute and an agitation rate at 1,700rpmand each of 150mgof rapamycin was added to the vessels. Fermentation was subsequently continued for 24 hours.
HPLCAnalysis
The fermentation broth (5 ml) was extracted with ethyl acetate (5 ml) followed by centrifugation on a Kokusan H-107 centrifuge at 3,000 rpm for 5 minutes. The organic layer was concentrated to dryness under reduced pressure and the obtained residue was redissolved in 500/d of ethanol. HPLCanalysis was performed on a Hewlett Packard HP1090 system. Samples (2.0/d) were loaded on a C18 reversed phase column (Senshu Pack ODS, 4.6 x 150mm) maintained at 42°C and eluted with linear gradient from methanol-water (7 : 3) to (10: 0) at a flow rate of 0.8 ml/minute in 30 minutes. Rapamycin analogs were monitored by absorbance at 287nm. Under these conditions, rapamycin analogs were eluted with a re- Table 6 ). Accordingly, the structure of CJ-12,452 was determined to be 28-dehydroxyrapamycin (Fig. 1) . The molecular formula of CJ-12,573, C5iH81NO12,corresponded to a loss of 14 mass units from rapamycin, indicating a deoxygenated derivative.
The 13C NMRspectrum of CJ-12,573 (Fig. 3) showed loss of the carbonyl signal ofC-9 (3 192.1) , together with up field displacement of the C-9 methylene signal at 3 38.0 assigned by "C^H COSY experiments (Fig. 4) . Fromthese results, the structure of CJ-12,573 was determined to be 9-deoxorapamycin. The molecular formulas of CJ-12,575 and CJ-12,578 were determined to be CsoH-^NOn and C^H^NO^, respectively. The former corresponded to a loss of 30 mass units from 9-deoxorapamycin (CJ-12,573), indicating a demethoxylated derivative.
As shown in Table 6 , the *H NMR spectrum of CJ-12,575 indicated a loss of the methoxy VOL.48 NO.7 THE JOURNAL OF ANTIBIOTICS -39 (S 3.30) , indicating the eliminations of a methoxy group at C-27 and O-demethylation at C-39. Accordingly, the structures of CJ-12,575 and CJ-12,578 were determined to be 9-deoxo-27-demethoxyrapamycin and 9-deoxo-27-demethoxy-39-O-demethyrapamycin, respectively (Fig. 1) . The cultured broth (6 liters column (50 x 750mm) and eluted with methanol to give a brown oily residue (2.5g). A part (20mg) of the residue was subjected to a reversed phase HPLCcolumn (Chemcosorb 5ODS-UH, 20 x 250mm) and eluted with methanol-water (8 : 2) at a flow rate of 5 ml/minute. The eluted peaks were collected to yield rapamycin analogs, CJ-12,225 (3.0mg) and CJ-12,263 (1.5mg).
Mixture of CJ-12,264 and CJ-12,265 was subjected to a silica gel HPLC column 20x250mm ) and eluted with chloroform-methanol (98 : 2), affording rapamycin analogs, 264 (3.0mg) and CJ-12,265 (3.0 mg). Molecular formulas 265 were determined to be all C50H77NO13, which corresponded to a loss of 14 mass units from rapamycin. the structure of CJ-12,265 was determined to be 27-0-demethylrapamycin23) (Fig. 1) . The molecular formula of CJ-12,225, C49H75NO13,corresponded to a loss of 28 mass units from rapamycin. As shown in Table 6 , the XHNMRspectrum of CJ-12,225 indicated the absence of 2 methoxy signals at 3 3.13 and 3.34, together with down field displacements of H-16 (3 4.02) and H-27 (3 4.17), respectively.
The structure of CJ-12,225 was therefore determined to be 1 6,27-0-bisdemethylrapamycin24) (Fig.  1) . 798 The fermentation broth (6 liters) was diluted with 6
liters of methanol and then loaded on a Diaion HP20 (1 liter) column. After washing with 50% aqueous acetone, 797, 798 and rapamycin were eluted with 3 liters of 90% aqueous acetone. The eluate was concentrated to aqueous solution (1 liter) and then extracted twice with 1 liter of ethyl acetate. The ethyl acetate layer was dried over anhydrous Na2SO4and evaporated to give a brown oily residue (0.9g). A part of the residue (50mg) was subjected to an ODScolumn (Chemcosorb 5ODS-UH, 20x 250mm) and eluted with methanolwater (8:2) at a flow rate of 5ml/minute. The eluted peaks were collected to yield rapamycin analogs, 797 (3.7mg) and CJ-12,798 (2.0mg). The molecular formula of CJ-12,797,^oH^NC^, corresponded to a loss of 14 mass units from rapamycin. Amino acid analysis of the hydrolysates of 798 was carried out after treatment with 6n HC1at 115°C for 16 hours. Each of the hydrolysates was analyzed by HPLC, using a chiral column (SUMICHIRALOA-5,000, 4.6 x 150mm). Both compounds were found to contain L-proline. The 13C NMRspectrum of CJ-12,797 indicated a loss of methylene signal of C-4 at 3 20.58, together with down filed displacement of C-2 (3 58.82) as shown in Table 7 . These results identified CJ-12,797 to be prolylrapamycin25). The molecular formula of CJ-12,798, C^H-^NO^, corresponded to a loss of 14 mass units from prolylrapamycin. The *H NMRspectrum of CJ-12,798 indicated a loss of the methoxy signal at 3 3.34, together with down field displacement of H-27 (<5 4.29, see Table 6 ). Based on the results described above, the structure of CJ-12,798 was determined to be 27-O-demethylprolylrapamycin (Fig. 1) .
CJ-12,434
The fermentation broth (6 liters) was diluted with 6 665 liters of methanol and then loaded on a Diaion HP20 (1 liter) column. After washing with 50% aqueous acetone, 434 and rapamycin were eluted with 3 liters of 90% aqueous acetone. The eluate was further purified by the same method as that ofCJ-12,797 and CJ-12,798, resulting in yielding a rapamycin analog, CJ-12,434 (44.0mg).
Molecular formula of CJ-12,434 was determined to be C50H77NO13,which corresponded to a loss of 14 mass units from rapamycin. Selected proton chemical shifts in CJ-12,434 and rapamycin are shown in Table 6 . The methoxy signal at d 3.41 disappeared together with down field displacement of H-39 (d 3.43), indicating 39-0-demethylrapamycin (Fig. 1) .
Amino Acid Analysis of 798 CJ-12,797 (1 mg) was hydrolyzed with 6n HC1 (1 ml) at 115°C in a sealed tube for 16 hours. Hydrolyzate was concentrated to dryness and dissolved in water (1 ml). The solution was loaded on a Dowex50Wx4column (5ml) and eluted with 5% NH4OHin water. The eluate was concentrated to dryness and redissolved in water 
Assessment of ImmunosuppressiveActivity
The immunosuppressive activity of the isolated compounds was determined in MLR.Humanfresh lymphocytes were separated from the heparinized blood of normal volunteers using Ficoll-Paque (Pharmacia) density gradient centrifugation.
Stimulator cells were prepared in the same wayand stored in liquid nitrogen. Fresh lymphocytes (5 x 104) were cultured in the presence of thawed stimulator cells (5x 104) with of without isolated compounds for 5 days at 37°C in the 5% CO2-humidified air, water-jacketed incubator. After 5 days of incubation, each well was pulsed with 3H-thymidine (0.5/iCi/well, 20Ci/mmol; NEN) for an additional 18
hours. The cells were harvested onto glass filters, dried and counted in liquid scintillation cocktail. For the mitogen-stimulated proliferation assay, murine splenic cells and humanMNCs were used. Murinesplenic cells were prepared from C3H/HeNmice according to standard procedure. HumanMNCs were prepared as described above. Microculture was performed in roundbottomed microtiter plates (1 x 105 cells/well). Proliferation was induced by the addition of concanavalin A (10 /ig/ml) or ionomycin (250 ng/ml)/phorbol myristate acetate (20 ng/ml) or lipopolysaccharide (10 /xg/ml). Cell division was assessed by the addition of 0.1 /iCi/well of 3H-thymidine for the last 4 hours of 48-hour incubation. Cells were harvested and counted as described above.
